AKTS (Aktis Oncology) PEG Ratio: N/A (As of Jul. 03, 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.76
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Aktis Oncology's PE Ratio without NRI is 0.00. Aktis Oncology's 5-Year EBITDA growth rate is 0.00%. Therefore, Aktis Oncology's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Aktis Oncology's PEG Ratio or its related term are showing as below:



AKTS's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.02
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Aktis Oncology  (NAS:AKTS) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Aktis Oncology PEG Ratio Related Terms

Aktis Oncology PEG Ratio Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology PEG Ratio Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PEG Ratio
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AKTS vs ZBIO, MLTX, AVBP: PEG Ratio Comparison

For the Biotechnology subindustry, Aktis Oncology's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aktis Oncology PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's PEG Ratio falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Aktis Oncology's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.76
Price